Xeris Biopharma Holdings, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

XERS$15.20+16.2%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of March and December 31,

Condensed Consolidated Balance Sheets

(in thousands, except share and par value)

	March 31, 2026	December 31, 2025
Assets · (unaudited)
Current assets:
Cash and cash equivalents	$111,750	$111,042
Trade accounts receivable, net	56,295	51,050
Inventory, net	74,234	68,673
Prepaid expenses and other current assets	9,403	9,548
Total current assets	251,682	240,313
Property and equipment, net	5,033	4,945
Operating lease right-of-use assets	21,949	22,112
Goodwill	22,859	22,859
Intangible assets, net	85,368	88,078
Other assets	5,122	5,220
Total assets	$392,013	$383,527
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$11,467	$3,076
Current operating lease liabilities	6,271	6,232
Other accrued liabilities	32,287	33,155
Accrued trade discounts and rebates	45,492	43,253
Accrued returns reserve	18,723	18,969
Other current liabilities	4,353	4,889
Total current liabilities	118,593	109,574
Long-term debt, net of unamortized debt issuance costs	221,224	220,335
Non-current operating lease liabilities	31,058	31,531
Other liabilities	8,127	8,398
Total liabilities	379,002	369,838
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2026 and December 31, 2025	—	—
Common stock—par value $0.0001, 350,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 172,558,783 and 166,215,410 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	18	17
Additional paid in capital	682,090	685,004
Accumulated deficit	(669,073)	(671,307)
Accumulated other comprehensive loss	(24)	(25)
Total stockholders' equity	13,011	13,689
Total liabilities and stockholders' equity	$392,013	$383,527

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data, unaudited)

	Three Months Ended March 31,
	2026	2025
Product revenue, net	$82,454	$57,802
Royalty, contract and other revenue	673	2,317
Total revenue	83,127	60,119
Costs and expenses:
Cost of goods sold	10,574	8,728
Research and development	8,783	7,753
Selling, general and administrative	53,144	44,018
Amortization of intangible assets	2,710	2,710
Total costs and expenses	75,211	63,209
Income (loss) from operations	7,916	(3,090)
Other income (expense):
Interest and other income	1,202	1,175
Interest expense	(6,884)	(7,305)
Total other expense	(5,682)	(6,130)
Net income (loss) before income taxes	2,234	(9,220)
Income tax benefit	—	—
Net income (loss)	$2,234	$(9,220)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	1	—
Comprehensive income (loss)	$2,235	$(9,220)
Net income (loss) per common share - basic	$0.01	$(0.06)
Net income (loss) per common share - diluted	$0.01	$(0.06)
Weighted average common shares outstanding:
Basic	170,523,208	152,445,935
Diluted	177,631,154	152,445,935

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.